Sin J H, Elshaboury R H, Hurtado R M, Letourneau A R, Gandhi R G
Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
J Clin Pharm Ther. 2018 Apr;43(2):291-295. doi: 10.1111/jcpt.12630. Epub 2017 Sep 11.
There is a lack of data regarding therapeutic drug monitoring (TDM) of antitubercular agents in the setting of continuous venovenous haemofiltration (CVVH). We describe TDM results of numerous antitubercular agents in a critically ill patient during CVVH and haemodialysis.
A 49-year-old man was initiated on treatment for disseminated Mycobacterium tuberculosis. During hospital admission, the patient developed critical illness and required renal replacement therapy. TDM results and pharmacokinetic calculations showed adequate serum concentrations of rifampin, ethambutol and amikacin during CVVH and of rifampin, pyrazinamide, ethambutol and levofloxacin during intermittent haemodialysis.
The presence of critical illness and renal replacement therapy can induce pharmacokinetic changes that may warrant vigilant TDM to ensure optimal therapy. To our knowledge, this is the first report to describe TDM for several antitubercular agents during CVVH in a critically patient with disseminated M. tuberculosis.
